Recommendations for measuring HIV reservoir size in cure-directed clinical trials

The BEAT-HIV Delaney Collaboratory to Cure HIV-1 infection

Research output: Contribution to journalArticlepeer-review

Abstract

Therapeutic strategies are being clinically tested either to eradicate latent HIV reservoirs or to achieve virologic control in the absence of antiretroviral therapy. Attaining this goal will require a consensus on how best to measure the numbers of persistently infected cells with the potential to cause viral rebound after antiretroviral-therapy cessation in assessing the results of cure-directed strategies in vivo. Current measurements assess various aspects of the HIV provirus and its functionality and produce divergent results. Here, we provide recommendations from the BEAT-HIV Martin Delaney Collaboratory on which viral measurements should be prioritized in HIV-cure-directed clinical trials.

Original languageEnglish (US)
Pages (from-to)1339-1350
Number of pages12
JournalNature medicine
Volume26
Issue number9
DOIs
StatePublished - Sep 1 2020

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Recommendations for measuring HIV reservoir size in cure-directed clinical trials'. Together they form a unique fingerprint.

Cite this